China Pharma Holdings, Inc. (CPHI) Reports Q3 Loss of $0.04

China Pharma Holdings, Inc. (NYSE: CPHI) reported Q3 EPS of ($0.04), versus ($0.05) reported last year. Revenue for the quarter came in at $2.3 million, versus $3.16 million reported last year.

In a statement from Ms. Zhilin Li, China Pharma\'s Chairman and CEO, "It is the Company's top priority to actively and steadily increase sales. We experienced certain market fluctuations in the third quarter of 2018, but through the continued implementation of sales promotions, our sales revenue in the first nine months of 2018 was comparable to the same period a year ago. Management will continue to vigorously promote sales through active participation in recent provincial market openings to receive new drug tender offers and through further penetration into the market." Ms. Li continued, "The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will continue to have a significant impact on the current performance and future development of Chinese pharmaceutical manufacturers, including us, and may gradually change business patterns of the industry. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market, in order to optimize our development strategy."

For earnings history and earnings-related data on China Pharma Holdings, Inc. (CPHI) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Mannatech (MTEX) Tops Q2 EPS by 53c
• Southland Holdings (SLND) Misses Q2 EPS by 122c